A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patietns with Nonhematological Malignancies, followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
|Effective start/end date||8/31/10 → 8/31/14|
- MILLENNIUM PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.